<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241028063523N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-11-06</date_registration>
      <primary_sponsor>Armed forces Hospital PNS Shifa Karachi,Pakistan</primary_sponsor>
      <public_title>Comparative efficacy of bifonazole and clotrimazole in the treatment of pitryasis versicolor</public_title>
      <acronym></acronym>
      <scientific_title>Comparative efficacy of bifonazole and clotrimazole in the treatment of pitryasis versicolor</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79893</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: All patients presenting in OPD of dermatology Department of PNS Shifa hospital fulfilling inclusion criteria will be included.
Patients will be divided into groups using lottery method.</study_design>
      <phase>4</phase>
      <hc_freetext>Pitryasis versicolor is a chronic cutaneous fungal infection caused by proliferation of lipophilic yeast (malassezia species) in stratum corneum..</hc_freetext>
      <i_freetext>Intervention 1: Clinically and mycologically confirmed cases of Pitryasis versicolor shall be divided into 2 groups. Group 1 and Group 2.                                                                                             INTERVENTION GROUP 1 will have 30 patients and they will be recieving bifonazole 1% w/w cream under trade name of BIFOMYK( manufactured by Bioglan pharma. Pakistan ) topical application twice daily for a period of 4 weeks. Response to treatment,disease recurrence and any local or systemic side effects will be checked after 2 and 4 weeks from starting the treatment and they will be followed up for 1 month after stopping the treatment,clinically and with lab investigations by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                                          Patients will be adviced at the time of prescription to apply thin layer of cream that would be absorbed over leisions. Otherwise there is no educational session in this study.                                                                                                      The response of treatment shall be entered in pre designed performa to assess the efficacy of 2 therapeutic agents bifonazole and clotrimazole clinically by by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                  The data  will be entered and analyzed by using SPSS statistical package version 21 software                                                                               . Intervention 2: INTERVENTION GROUP 2 will have 30 patients and they will be recieving clotrimazole 1% w/w cream under trade name of CANESTEN ( manufactured by Bayer pakistan pvt. Ltd ), topical application twice daily for a period of 4 weeks. Response to treatment, disease recurrence and any local or systemuc side effects will be checked after 2 weeks, 4 weeks from starting the treatment and they will be followed up for 1 month after stopping the treatment, clinically and with lab investigation by absence of yellow floresence on woods lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                                      Patients will be adviced at the time of prescription to apply small amout of cream that would be absorbed over leisions. Otherwise there is no educational session in this study.                                                                                                      The response of treatment shall be entered in pre designed performa to assess the efficacy of 2 therapeutic agents bifonazole and clotrimazole clinically by by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                  The data  will be entered and analyzed by using SPSS statistical package version 21 software.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
APPENDIX 1: PERFORMA
Name, age, gender, address, contact number, weight, height, duration of disease, site group (A,B)
INFORMED CONSENT.

When:
After 6 months RCT, for 4 years.

To whom:
primary investigator

Conditions:
All patients in dermatology opd according to operational definition of pitryasis versicolor fullfilling the inclusion criteria.

Where to obtain:
administration of PNS SHIFA HOSPITAL

How to obtain:
contact to primary investigator

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Atiya Rahman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sailor street, DHA phase ll, PNS Shifa</address>
        <city>Karachi</city>
        <country1>Pakistan</country1>
        <zip>75500</zip>
        <telephone>+92 21 48506540</telephone>
        <email>sanasaleem20694@gmail.com</email>
        <affiliation>Armed forces Hospital, PNS Shifa</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Atiya Rahman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sailor street DHA phase ll near Kala pul</address>
        <city>Karachi</city>
        <country1>Pakistan</country1>
        <zip>75500</zip>
        <telephone>+92 21 48506540</telephone>
        <email>sanasaleem20694@gmail.com</email>
        <affiliation>Armed forces Hospital, PNS shifa</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients who will have clinically pitryasis versicolor as per operational definition
Patients within range of 18-60 years of age
Willing to provide informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with local inflammatory of infectious disease at the site to be treated or who will be allergic to topical medication
Previously treated patients
Patients delevelop side effects during study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B36.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pityriasis versicolor</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Clinically and mycologically confirmed cases of Pitryasis versicolor shall be divided into 2 groups. Group 1 and Group 2.                                                                                             INTERVENTION GROUP 1 will have 30 patients and they will be recieving bifonazole 1% w/w cream under trade name of BIFOMYK( manufactured by Bioglan pharma. Pakistan ) topical application twice daily for a period of 4 weeks. Response to treatment,disease recurrence and any local or systemic side effects will be checked after 2 and 4 weeks from starting the treatment and they will be followed up for 1 month after stopping the treatment,clinically and with lab investigations by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                                          Patients will be adviced at the time of prescription to apply thin layer of cream that would be absorbed over leisions. Otherwise there is no educational session in this study.                                                                                                      The response of treatment shall be entered in pre designed performa to assess the efficacy of 2 therapeutic agents bifonazole and clotrimazole clinically by by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                  The data  will be entered and analyzed by using SPSS statistical package version 21 software                                                                               .</i_keyword>
      <i_keyword>INTERVENTION GROUP 2 will have 30 patients and they will be recieving clotrimazole 1% w/w cream under trade name of CANESTEN ( manufactured by Bayer pakistan pvt. Ltd ), topical application twice daily for a period of 4 weeks. Response to treatment, disease recurrence and any local or systemuc side effects will be checked after 2 weeks, 4 weeks from starting the treatment and they will be followed up for 1 month after stopping the treatment, clinically and with lab investigation by absence of yellow floresence on woods lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                                      Patients will be adviced at the time of prescription to apply small amout of cream that would be absorbed over leisions. Otherwise there is no educational session in this study.                                                                                                      The response of treatment shall be entered in pre designed performa to assess the efficacy of 2 therapeutic agents bifonazole and clotrimazole clinically by by absence of yellow floresence on wood's lamp examination and absence of  fungal hyphae on microscopy after scrapping mount with potassium hydroxide.                                                                                                  The data  will be entered and analyzed by using SPSS statistical package version 21 software</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome of the study will focus on mycological cure ( negative microscopy of fungal hyphae by potassium hydroxide mount). Timepoint: Patient will be assessed before intervention, at 2 weeks and 4 weeks after intervention. Method of measurement: Method used to assess mycological cure will be skin scrapping mount with potassium hydroxide( negative for fungal hyphae).</prim_outcome>
      <prim_outcome>The primary outcome of the study will focus on alleviation of physical symptoms such as leision clearence ,erythema, pruritis, desqamation  and absence of yellow floresence on wood's lamp examination. Timepoint: Patient will be assessed Before intervention,at 2 weeks and 4 weeks after intervention. Method of measurement: Method used to assess clinical cure will be wood's lamp examination(absence of clinical signs).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Tolerability of drugs by monitoring side effects. Timepoint: At 2 weeks and at 4 weeks. Method of measurement: i will measure clinical cure by woods lamp examination(absence of signs) and mycological cure by skin scrapping (negative for fungal hyphae) and side effects (if any).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Armed forces Hospital PNS Shifa Karachi,Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-04-05</approval_date>
        <contact_name>Ethics Committee of PNS Shifa</contact_name>
        <contact_address>PNS Shifa Hospital.Sailor street DHA phase ll, near Kala pul. Karachi Sindh Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
